Redhill Retained Earnings vs Common Stock Analysis

RDHL Stock

USD 0.46 0.01 2.22%

Redhill Biopharma financial indicator trend analysis is much more than just breaking down Redhill Biopharma prevalent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Redhill Biopharma is a good investment. Please check the relationship between Redhill Biopharma Retained Earnings and its Common Stock accounts. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.

For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.

Retained Earnings vs Common Stock

Retained Earnings vs Common Stock Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Redhill Biopharma Retained Earnings account and Common Stock. At this time, the significance of the direction appears to have strong contrarian relationship.

The correlation between Redhill Biopharma's Retained Earnings and Common Stock is -0.64. Overlapping area represents the amount of variation of Retained Earnings that can explain the historical movement of Common Stock in the same time period over historical financial statements of Redhill Biopharma, assuming nothing else is changed. The correlation between historical values of Redhill Biopharma's Retained Earnings and Common Stock is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Retained Earnings of Redhill Biopharma are associated (or correlated) with its Common Stock. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Common Stock has no effect on the direction of Retained Earnings i.e., Redhill Biopharma's Retained Earnings and Common Stock go up and down completely randomly.

Correlation Coefficient

-0.64

Relationship Direction	Negative
Relationship Strength	Weak

View All Relationships

Retained Earnings

The cumulative amount of net income that a company retains for reinvestment in its operations, rather than distributing it to shareholders as dividends.

Common Stock

Most indicators from Redhill Biopharma's fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Redhill Biopharma current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.

For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.The value of Selling General Administrative is expected to slide to about 18.4 M. The value of Issuance Of Capital Stock is estimated to slide to about 13.3 M

Redhill Biopharma fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Other Liab	Accounts Payable	Cash	Long Term Debt	Common Stock Shares Outstanding	Short Term Investments	Other Current Assets	Total Liab	Preferred Stock Total Equity	Intangible Assets	Common Stock	Property Plant Equipment	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Non Current Assets Total	Non Currrent Assets Other	Other Assets	Cash And Short Term Investments	Net Receivables	Common Stock Total Equity	Non Current Liabilities Total
Total Assets		0.67	0.75	0.6	0.87	0.53	0.48	-0.13	0.0	0.22	0.91	0.28	0.95	-0.22	0.56	-0.24	0.83	0.76	-0.56	0.94	0.51	0.5	0.32	0.91	0.54	0.81
Other Current Liab	0.67		0.98	0.45	0.4	0.04	0.52	0.21	-0.3	0.25	0.85	-0.04	0.7	0.14	0.55	-0.76	0.8	0.88	-0.73	0.66	0.29	0.65	-0.18	0.84	0.55	0.31
Total Current Liabilities	0.75	0.98		0.49	0.49	0.11	0.53	0.14	-0.31	0.24	0.91	0.01	0.79	0.06	0.59	-0.73	0.88	0.92	-0.71	0.75	0.32	0.65	-0.14	0.9	0.55	0.42
Other Liab	0.6	0.45	0.49		0.61	0.39	0.41	0.3	-0.46	-0.13	0.63	-0.13	0.67	0.25	0.61	-0.36	0.54	0.5	-0.54	0.67	0.59	0.67	-0.07	0.63	0.49	0.64
Accounts Payable	0.87	0.4	0.49	0.61		0.4	0.57	0.12	0.03	0.07	0.74	-0.01	0.85	0.04	0.67	-0.1	0.68	0.58	-0.62	0.87	0.6	0.61	0.25	0.76	0.67	0.9
Cash	0.53	0.04	0.11	0.39	0.4		0.05	-0.37	0.26	-0.07	0.23	0.41	0.32	-0.41	-0.01	0.46	0.2	-0.08	-0.01	0.32	0.08	-0.14	0.8	0.22	0.1	0.33
Long Term Debt	0.48	0.52	0.53	0.41	0.57	0.05		0.65	-0.28	-0.23	0.53	-0.5	0.53	0.58	0.88	-0.38	0.68	0.49	-0.9	0.53	0.1	0.79	-0.17	0.53	0.94	0.39
Common Stock Shares Outstanding	-0.13	0.21	0.14	0.3	0.12	-0.37	0.65		-0.36	-0.21	0.04	-0.93	-0.02	0.99	0.66	-0.39	0.16	0.11	-0.71	-0.02	0.01	0.75	-0.49	0.05	0.7	-0.06
Short Term Investments	0.0	-0.3	-0.31	-0.46	0.03	0.26	-0.28	-0.36		0.6	-0.31	0.32	-0.26	-0.35	-0.42	0.73	-0.32	-0.4	0.29	-0.26	-0.26	-0.51	0.78	-0.31	-0.16	-0.21
Other Current Assets	0.22	0.25	0.24	-0.13	0.07	-0.07	-0.23	-0.21	0.6		0.15	0.23	0.11	-0.22	-0.14	0.05	0.09	0.21	0.04	0.08	0.02	-0.09	0.31	0.14	-0.1	-0.08
Total Liab	0.91	0.85	0.91	0.63	0.74	0.23	0.53	0.04	-0.31	0.15		0.13	0.96	-0.05	0.65	-0.61	0.91	0.94	-0.67	0.95	0.56	0.67	-0.06	1.0	0.56	0.75
Preferred Stock Total Equity	0.28	-0.04	0.01	-0.13	-0.01	0.41	-0.5	-0.93	0.32	0.23	0.13		0.17	-0.95	-0.51	0.28	0.0	0.05	0.52	0.17	0.03	-0.61	0.49	0.12	-0.54	0.16
Intangible Assets	0.95	0.7	0.79	0.67	0.85	0.32	0.53	-0.02	-0.26	0.11	0.96	0.17		-0.11	0.68	-0.45	0.89	0.87	-0.6	1.0	0.59	0.63	0.03	0.96	0.55	0.87
Common Stock	-0.22	0.14	0.06	0.25	0.04	-0.41	0.58	0.99	-0.35	-0.22	-0.05	-0.95	-0.11		0.59	-0.35	0.07	0.03	-0.64	-0.11	-0.02	0.69	-0.51	-0.05	0.63	-0.13
Property Plant Equipment	0.56	0.55	0.59	0.61	0.67	-0.01	0.88	0.66	-0.42	-0.14	0.65	-0.51	0.68	0.59		-0.5	0.8	0.63	-0.9	0.68	0.22	0.9	-0.3	0.65	0.91	0.55
Total Stockholder Equity	-0.24	-0.76	-0.73	-0.36	-0.1	0.46	-0.38	-0.39	0.73	0.05	-0.61	0.28	-0.45	-0.35	-0.5		-0.56	-0.79	0.55	-0.43	-0.34	-0.68	0.76	-0.62	-0.33	-0.2
Property Plant And Equipment Net	0.83	0.8	0.88	0.54	0.68	0.2	0.68	0.16	-0.32	0.09	0.91	0.0	0.89	0.07	0.8	-0.56		0.87	-0.74	0.88	0.22	0.67	-0.09	0.89	0.69	0.61
Net Debt	0.76	0.88	0.92	0.5	0.58	-0.08	0.49	0.11	-0.4	0.21	0.94	0.05	0.87	0.03	0.63	-0.79	0.87		-0.65	0.85	0.51	0.69	-0.32	0.95	0.49	0.62
Retained Earnings	-0.56	-0.73	-0.71	-0.54	-0.62	-0.01	-0.9	-0.71	0.29	0.04	-0.67	0.52	-0.6	-0.64	-0.9	0.55	-0.74	-0.65		-0.59	-0.23	-0.92	0.22	-0.67	-0.96	-0.4
Non Current Assets Total	0.94	0.66	0.75	0.67	0.87	0.32	0.53	-0.02	-0.26	0.08	0.95	0.17	1.0	-0.11	0.68	-0.43	0.88	0.85	-0.59		0.61	0.63	0.03	0.95	0.55	0.9
Non Currrent Assets Other	0.51	0.29	0.32	0.59	0.6	0.08	0.1	0.01	-0.26	0.02	0.56	0.03	0.59	-0.02	0.22	-0.34	0.22	0.51	-0.23	0.61		0.47	-0.11	0.59	0.14	0.75
Other Assets	0.5	0.65	0.65	0.67	0.61	-0.14	0.79	0.75	-0.51	-0.09	0.67	-0.61	0.63	0.69	0.9	-0.68	0.67	0.69	-0.92	0.63	0.47		-0.44	0.68	0.84	0.52
Cash And Short Term Investments	0.32	-0.18	-0.14	-0.07	0.25	0.8	-0.17	-0.49	0.78	0.31	-0.06	0.49	0.03	-0.51	-0.3	0.76	-0.09	-0.32	0.22	0.03	-0.11	-0.44		-0.08	-0.08	0.07
Net Receivables	0.91	0.84	0.9	0.63	0.76	0.22	0.53	0.05	-0.31	0.14	1.0	0.12	0.96	-0.05	0.65	-0.62	0.89	0.95	-0.67	0.95	0.59	0.68	-0.08		0.55	0.77
Common Stock Total Equity	0.54	0.55	0.55	0.49	0.67	0.1	0.94	0.7	-0.16	-0.1	0.56	-0.54	0.55	0.63	0.91	-0.33	0.69	0.49	-0.96	0.55	0.14	0.84	-0.08	0.55		0.41
Non Current Liabilities Total	0.81	0.31	0.42	0.64	0.9	0.33	0.39	-0.06	-0.21	-0.08	0.75	0.16	0.87	-0.13	0.55	-0.2	0.61	0.62	-0.4	0.9	0.75	0.52	0.07	0.77	0.41

Click cells to compare fundamentals

Redhill Biopharma Account Relationship Matchups

Redhill Biopharma fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	74.1M	180.2M	181.2M	158.9M	23.0M	21.9M
Other Current Liab	107K	18.3M	30.9M	77.0M	15.2M	12.9M
Total Current Liabilities	10.6M	73.2M	81.5M	197.5M	19.2M	33.1M
Other Liab	844K	500K	7.9M	4.6M	5.3M	2.8M
Accounts Payable	4.2M	11.6M	11.7M	4.2M	3.3M	4.2M
Cash	29.0M	29.3M	29.5M	20.0M	6.4M	6.0M
Common Stock Shares Outstanding	742.3K	910.7K	1.2M	1.5M	6.5M	6.8M
Short Term Investments	29.8M	24.2M	18.8M	498K	8.5M	0.0
Other Current Assets	2.2M	5.5M	3.8M	19.6M	797.0K	757.2K
Total Liab	14.1M	166.4M	172.3M	207.3M	21.0M	19.9M
Intangible Assets	16.9M	87.9M	71.6M	65.6M	5.6M	5.3M
Common Stock	962K	1.1M	1.5M	2.8M	21.4M	22.5M
Property Plant Equipment	163K	3.8M	5.7M	4.2M	4.9M	5.1M
Total Stockholder Equity	60.0M	13.9M	8.9M	(48.4M)	2.1M	2.0M
Property Plant And Equipment Net	3.8M	5.7M	4.2M	7.2M	1.2M	2.0M
Net Debt	(25.2M)	57.6M	58.3M	102.7M	(5.2M)	(4.9M)
Retained Earnings	(208.4M)	(280.3M)	(367.9M)	(433.9M)	(407.7M)	(387.4M)
Non Current Assets Total	20.9M	109.7M	92.0M	73.0M	6.9M	6.6M
Non Currrent Assets Other	(20.7M)	16.2M	16.2M	150K	147K	139.7K
Cash And Short Term Investments	47.9M	29.8M	38.0M	20.0M	6.4M	6.0M
Net Receivables	1.2M	28.7M	32.5M	35.4M	3.3M	3.1M
Common Stock Total Equity	575K	767K	962K	1.1M	1.2M	1.3M
Liabilities And Stockholders Equity	74.1M	180.2M	181.2M	158.9M	23.0M	21.9M
Non Current Liabilities Total	3.5M	93.1M	90.8M	9.8M	1.7M	1.6M
Inventory	1.9M	6.5M	14.8M	11.0M	5.7M	6.0M
Other Stockholder Equity	267.4M	293.1M	375.2M	382.6M	388.4M	217.0M
Property Plant And Equipment Gross	3.8M	5.7M	5.0M	8.3M	2.4M	2.2M
Total Current Assets	53.2M	70.5M	89.2M	85.9M	16.1M	15.3M
Net Tangible Assets	45.9M	43.1M	(74.0M)	(62.8M)	(56.5M)	(53.7M)
Net Invested Capital	60.0M	95.3M	92.5M	66.8M	2.1M	2.0M
Net Working Capital	42.6M	(2.7M)	7.7M	(111.6M)	(3.1M)	(2.9M)
Capital Stock	962K	1.1M	1.5M	2.8M	21.4M	22.5M

Currently Active Assets on Macroaxis

MSFT	Microsoft
V	Visa Class A
DD	Dupont De Nemours
CRM	Salesforce
GM	General Motors

When determining whether Redhill Biopharma is a strong investment it is important to analyze Redhill Biopharma's competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Redhill Biopharma's future performance. For an informed investment choice regarding Redhill Stock, refer to the following important reports:

How To Invest In Redhill

Details

Is Redhill Stock a good investment?

Details

What is Redhill Biopharma's Net Worth?

Details

Largest Pharmaceuticals Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Redhill Biopharma. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in rate.

For more information on how to buy Redhill Stock please use our How to buy in Redhill Stock guide.

Note that the Redhill Biopharma information on this page should be used as a complementary analysis to other Redhill Biopharma's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.

Complementary Tools for Redhill Stock analysis

When running Redhill Biopharma's price analysis, check to measure Redhill Biopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Redhill Biopharma is operating at the current time. Most of Redhill Biopharma's value examination focuses on studying past and present price action to predict the probability of Redhill Biopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Redhill Biopharma's price. Additionally, you may evaluate how the addition of Redhill Biopharma to your portfolios can decrease your overall portfolio volatility.

	Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing
	Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market.
	Commodity Directory Find actively traded commodities issued by global exchanges
	Analyst Advice Analyst recommendations and target price estimates broken down by several categories
	Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk
	Piotroski F Score Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
	Performance Analysis Check effects of mean-variance optimization against your current asset allocation
	ETFs Find actively traded Exchange Traded Funds (ETF) from around the world
	Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings
	Economic Indicators Top statistical indicators that provide insights into how an economy is performing
	Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
	Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules
	Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios

Is Redhill Biopharma's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Redhill Biopharma. If investors know Redhill will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Redhill Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

Revenue Per Share

1.008

Quarterly Revenue Growth

(0.96)

Return On Assets

(0.16)

Return On Equity

(8.84)

The market value of Redhill Biopharma is measured differently than its book value, which is the value of Redhill that is recorded on the company's balance sheet. Investors also form their own opinion of Redhill Biopharma's value that differs from its market value or its book value, called intrinsic value, which is Redhill Biopharma's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Redhill Biopharma's market value can be influenced by many factors that don't directly affect Redhill Biopharma's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Redhill Biopharma's value and its price as these two are different measures arrived at by different means. Investors typically determine if Redhill Biopharma is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Redhill Biopharma's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Redhill Retained Earnings vs Common Stock Analysis

Retained Earnings vs Common Stock

Retained Earnings vs Common Stock Correlation Analysis

Correlation Coefficient

Retained Earnings

Common Stock

Redhill Biopharma fundamental ratios Correlations

Redhill Biopharma Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Redhill Biopharma fundamental ratios Accounts

Currently Active Assets on Macroaxis

Complementary Tools for Redhill Stock analysis

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Net Receivables	+ 1.0	Total Liab
Non Current Assets Total	+ 1.0	Intangible Assets
Common Stock	+ 0.99	Common Stock Shares Outstanding
Total Current Liabilities	+ 0.98	Other Current Liab
Intangible Assets	+ 0.96	Total Liab
Net Receivables	+ 0.96	Intangible Assets

Common Stock Total Equity	- 0.96	Retained Earnings
Common Stock	- 0.95	Preferred Stock Total Equity
Preferred Stock Total Equity	- 0.93	Common Stock Shares Outstanding
Other Assets	- 0.92	Retained Earnings
Retained Earnings	- 0.9	Property Plant Equipment
Retained Earnings	- 0.9	Long Term Debt